Xencor Inc (NASDAQ:XNCR) major shareholder John S. Stafford III sold 37,951 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $38.68, for a total value of $1,467,944.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Shares of NASDAQ:XNCR traded up $0.94 during midday trading on Monday, reaching $35.80. 373,741 shares of the company’s stock traded hands, compared to its average volume of 329,833. Xencor Inc has a 1 year low of $27.75 and a 1 year high of $46.33. The company has a market cap of $2.03 billion, a P/E ratio of -27.33 and a beta of 1.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.92 and a current ratio of 8.92. The company has a fifty day simple moving average of $38.06 and a two-hundred day simple moving average of $38.13.
Xencor (NASDAQ:XNCR) last announced its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.40. Xencor had a return on equity of 5.84% and a net margin of 21.60%. The firm had revenue of $21.76 million for the quarter, compared to analyst estimates of $4.62 million. As a group, research analysts forecast that Xencor Inc will post 0.5 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in XNCR. First Trust Advisors LP lifted its position in shares of Xencor by 185.4% during the 1st quarter. First Trust Advisors LP now owns 69,783 shares of the biopharmaceutical company’s stock valued at $2,167,000 after buying an additional 45,331 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its stake in Xencor by 64.6% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 26,809 shares of the biopharmaceutical company’s stock valued at $1,097,000 after purchasing an additional 10,520 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Xencor by 42.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,911 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 1,160 shares during the last quarter. Aperio Group LLC acquired a new position in Xencor in the 2nd quarter valued at $152,000. Finally, DekaBank Deutsche Girozentrale raised its stake in Xencor by 63.7% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 29,800 shares of the biopharmaceutical company’s stock valued at $1,207,000 after purchasing an additional 11,600 shares during the last quarter. Hedge funds and other institutional investors own 92.43% of the company’s stock.
Several equities research analysts have commented on XNCR shares. Leerink Swann lowered their price objective on Xencor from $52.00 to $44.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Zacks Investment Research lowered Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, November 16th. ValuEngine lowered Xencor from a “strong-buy” rating to a “buy” rating in a research report on Sunday. BidaskClub lowered Xencor from a “buy” rating to a “hold” rating in a research report on Tuesday, December 31st. Finally, Guggenheim started coverage on Xencor in a research report on Wednesday, November 20th. They issued a “hold” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. Xencor presently has an average rating of “Buy” and a consensus price target of $43.90.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
See Also: What is a Swap?
Receive News & Ratings for Xencor Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Xencor and related companies with MarketBeat.com’s FREE daily email newsletter.